12.03.2024 • Newsinvestmentbiologics

Kyowa Kirin to Build First US Pharma Operations

Japan-based pharmaceutical company Kyowa Kirin plans to build a $200 million biologics manufacturing center in Sanford, North Carolina, creating 102 jobs. This will be the company’s first North American pharmaceutical manufacturing operation, expected to create 102 jobs.

“Establishing a new center of excellence for biologics manufacturing in North America is a testament to the promising potential we see in our pipeline,” said Paul Testa, Kyowa Kirin’s executive vice president Supply Chain & Manufacturing, North America. “We believe the Sanford facility will become a vital part of our global manufacturing network – helping us train employees, deliver medicines with life-changing value, and support our future growth as a region and as a global business.”

The project in North Carolina will be facilitated, in part, by a Job Development Investment Grant (JDIG) awarded to Kyowa Kirin North America Manufacturing.

Kyowa Kirin expects to complete the project in four years.

© REB Images/Getty Images
© REB Images/Getty Images

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read